Abstract:Amyloid- β peptides (Aβ) participate in the development of Alzheimer's disease (AD). AD brains accumulate multiple forms of Aβ peptides, composed of Aβ(1–40/42) with pyroglutamate-Aβ(3–40/42) (pGlu-A β) present as a major portion of Aβ. Several studies estimate that pGlu-A β comprises approximately 50% or more of total A β (Saido et al., 1995; Kuo et al., 1997). The pGlu-Aβ(3–40/42) is hypothesized to facilitate the oligomerization of Aβ(1–40/42) (Schilling et al., 2006) to result in neurotoxicity. The formation of pGlu-Aβ(3–40/42) is produced from the substrate Aβ(3–40/42), which may be generated by a beta-secretase-dependent or -independent mechanism. Cathepsin B has been shown to generate A β(1–40/42) from AD mice expressing APP with the wild-type beta-secretase site (Kindy et al., 2012) expressed in the majority of AD patients. This study, therefore, addresses the role of cathepsin B, possessing wild-type beta-secretase function, in producing pGlu-Aβ(3–40/42). Knockout of the cathepsin B gene was conducted in the APP/Lon mouse model of AD. The APP/Lon mice were also treated with E64d, inhibitor of cathepsin B, by oral administration. Brains were then assessed for levels of pGlu-Aβ(3–40/42) and Aβ(1–40/42), amyloid plaque; animals were evaluated for memory function by the Morris water maze test. Knockout of the cathepsin B gene in the APP/Lon AD mouse model, expressing APP with the wild-type beta-secretase site, was assessed. Knockout of the cathepsin gene resulted in a significant reduction in brain pGlu-Aβ(3–40/42) as well as Aβ(1–40/42). Chemical inhibition of cathepsin B, conducted by oral administration of the E64d inhibitor, in the APP/Lon mice reduced brain pGlu-Aβ(3–40/42) and Aβ(1–40/42). Also, cathepsin B inhibition and gene knockout reduced brain amyloid plaque accumulation and improved memory function in the APP/Lon mice. Cellular studies show that pGlu-Aβ(3–40) is secreted from the regulated secretory pathway of neuronal-like chromaffin cells, and inhibition of cathepsin B (with CA074Me) reduces pGlu-A β(3–40). Results from knockout of the cathepsin B gene in the APP/Lon AD mouse model show that cathepsin B participates in the production of pGlu-Aβ(3–40/42), as well as A β(1–40/42). Cathepsin B inhibitors will likely be effective at reducing neurotoxic pGlu-Aβ(3–40/42), as well as Aβ(1–40/42), for improvement of memory function in AD.

BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer's Disease: Differential Aβ Antibody Labeling of Early-Onset Axon Terminal Pathology.

Β‐secretase‐1 Elevation in Transgenic Mouse Models of Alzheimer’s Disease is Associated with Synaptic/axonal Pathology and Amyloidogenesis: Implications for Neuritic Plaque Development

Beta Secretase Localization, Amyloid Deposition And Aberrant Synaptic And Neuritic Sprouting In Transgenic Mouse Alzheimer Models: A Role For Bace1 In Synaptic Remodeling And Plaque Formation?

Beta-Secretase-1 Elevation In Transgenic Mouse Models Of Alzheimer'S Disease Is Associated With Synaptic/Axonal Pathology And Amyloidogenesis: Implications For Neuritic Plaque Development

Β‐secretase‐1 Elevation in Aged Monkey and Alzheimer’s Disease Human Cerebral Cortex Occurs Around the Vasculature in Partnership with Multisystem Axon Terminal Pathogenesis and Β‐amyloid Accumulation

O4‐02‐01: A Novel Role of Beta‐secretase1 (BACE1) in the Pathogenesis of Cerebral Amyloid Angiopathy (CAA)

β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation

A Novel Role Of Beta-Secretase 1 (Bace1) In The Pathogenesis Of Cerebral Amyloid Angiopathy (Caa)

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

Amyloid Plaque Pathogenesis in 5XFAD Mouse Spinal Cord: Retrograde Transneuronal Modulation after Peripheral Nerve Injury

Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study

The Amyloid Precursor Protein Modulates the Position and Length of the Axon Initial Segment

Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes

Association Between Axonopathy and Amyloid Plaques in the Spinal Cord of the Transgenic Mice of Alzheimer's Disease

Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease

Β-Amyloid Accumulation Enhances Microtubule Associated Protein Tau Pathology in an APPNL-G-F/MAPTP301S Mouse Model of Alzheimer’s Disease

O1–08–02: Cathepsin B Produces Brain Pyro‐glu‐beta‐amyloid in a Transgenic Alzheimer's Disease Mouse Model

Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.

BAG-1M Co-Activates BACE1 Transcription Through NF-κB and Accelerates Aβ Production and Memory Deficit in Alzheimer's Disease Mouse Model.

Chronic Temporal Lobe Epilepsy is Associated with Enhanced Alzheimer-like Neuropathology in 3×Tg-Ad Mice.

Alzheimer's Β-Secretase (BACE1) Regulates the Camp/pka/creb Pathway Independently of Β-Amyloid.